ArticleBreast cancer (Dove Medical Press)2026
IFI44 Orchestrates an IL-10-Driven M2 Macrophage Program in Breast Cancer: An Immune Prognostic Signature.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although IFI44 is recognized for its crucial role in autoimmune disorders, its function in breast cancer (BC) remains unclear. This study aimed to investigate the immune-related and prognostic significance of IFI44 in BC. Methods: Bio-informatics analysis and in vitro experiments were performed to assess BC cells' proliferation, migration, and invasion. Immune cell infiltration was analyzed using CIBERSORT and ESTIMATE algorithms. The correlation between IFI44 and M2 macrophage markers was validated via TIMER2 and GEPIA2 databases. An IFI44-related M2 macrophage signature (IMS) was constructed using LASSO Cox regression. Its prognostic performance and association with immunotherapy/chemotherapy response were evaluated using survival analysis, ROC curves, and drug sensitivity data (GDSC2). Results: IFI44 was highly expressed in BC and associated with poor prognosis. Down-regulation of IFI44 BC cells inhibited M2 macrophages proliferation, but exogenous IL-10 in the knockdown-IFI44 BC cells rescued this reduction in vitro. The constructed IMS, based on four genes (GPR171, KIR2DS4, NPAS1, CD79A), effectively predicted the overall survival (OS) of BC patients with high specificity and sensitivity. Of note, the IMS was applied in pan-cancer and we found it could accurately predict the prognosis and immune score in multiple cancers. Conclusion: IFI44 promotes BC progression and M2 macrophage infiltration via an IL-10-mediated mechanism. IFI44 represents a promising target for immunotherapy in breast cancer. Our investigation identified that IFI44-based IMS provides a predictive scenario to determine the treatment and prognosis of cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.